Key result
Bivalirudin therapy was associated with a lower rate of in-hospital death compared with heparin plus a GP IIb/IIIa inhibitor in STEMI patients undergoing primary PCI (3.2% vs 4.0%; P=0.011).
Why the study?
Does bivalirudin reduce in-hospital death and bleeding compared to heparin+GPI in STEMI patients undergoing primary PCI?
Observational (n=21,316)
Yes
Does bivalirudin reduce in-hospital death and bleeding compared to heparin+GPI in STEMI patients undergoing primary PCI?
Absolute Event Rate: 3.2% vs 4%
p-value: p=0.011
In real-world practice, bivalirudin during primary PCI for STEMI is associated with lower in-hospital mortality, less bleeding, and reduced costs compared to heparin plus a glycoprotein IIb/IIIa inhibitor.
No takes yet. Share an insight, caveat, or question.
Bivalirudin was associated with lower mortality in this propensity-matched cohort; should not yet change practice and leaves open the need for randomized confirmation.
Pinto et al. (2012) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=21,316). Bivalirudin vs. Heparin + GP IIb/IIIa receptor inhibitor (heparin+GPI) was evaluated on In-hospital death (p=0.011). Bivalirudin therapy was associated with a lower rate of in-hospital death compared with heparin plus a GP IIb/IIIa inhibitor in STEMI patients undergoing primary PCI (3.2% vs 4.0%; P=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: